# Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic Decompensation

> **NCT02084160** · — · COMPLETED · sponsor: **Meridian Bioscience, Inc.** · enrollment: 579 (actual)

## Conditions studied

- Chronic Liver Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02084160
- **Lead sponsor:** Meridian Bioscience, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2018-10
- **Final completion:** 2018-11
- **Target enrollment:** 579 (ACTUAL)
- **Last updated:** 2022-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02084160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02084160, "Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic Decompensation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02084160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*